Investor Presentaiton

Pharmaceuticals Segment Highlights - Q3'FY20 (1/2) Particulars¹ Revenue Specialty Pharma CDMO Q3'FY19 Q3'FY20 % Change ■ Pharmaceuticals revenue at Rs 1,450 Crore, an increase of 2% YoY. 1,424 1,450 2% ■ 757 764 1% 374 393 5% Generics 293 293 0% Reported EBITDA 388 411 6% • Adjusted EBITDA 383 414 8% Reported EBITDA Margin (%) 27.2% 28.4% · Adjusted EBITDA Margin (%) 26.9% 28.6% Specialty Pharma and CDMO segments increased by 1% YoY and 5% YoY, respectively. Generics revenue was flat YoY Specialty Pharmaceuticals² (53% of Pharma Revenues) • CDMO³ Steady performance in Radiopharma business continues, led by higher volumes in key products like Ruby-FillⓇ Received favorable ruling from U.S. International Trade Commission in Ruby-Fill® Allergy business witnessed revenue growth both YoY and QoQ led by higher volumes in venom and allergenic extracts 43 40 Geography Wise Revenue¹ 1,151 1,196 136 120 94 94 India North America Europe & Japan ROW Q3'FY19 ■Q3'FY20 1. All figures are in Rs Crore unless otherwise stated 2. Specialty Pharmaceuticals comprises Radiopharma and Allergy Therapy Products businesses 3. Contract Development and Manufacturing (CDMO) business comprises CMO and API businesses • • • • Steady performance witnessed in CMO business; robust outlook due to strong order book and new deals Initiatives taken to increase total capacity by over 30% with annual potential revenues of around USD 30 million O Increased shifts to 24x7 on Line 2 from Q3'FY19 and on line 1 from Q3'FY20 onwards New Lyo equipment installed at line 2 at the Spokane facility with commercialisation expected during Q4'FY20 In API, revenue growth witnessed on account of higher volumes and better prices Company working diligently with the US FDA and Health Canada, regarding the resolution of the Official Action Indicated (OAI) in Nanjangud JUBILANT LIFESCIENCES

View entire presentation